Fate Therapeutics, Inc.

FATE

NASDAQ

Healthcare

Biotechnology

San Diego, CA, US181 employeesfatetherapeutics.com

$1.22

-0.02(-1.61%)

Mkt Cap $142M

$0.91

$1.67

52-Week Range

At A Glance

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

Revenue is primarily driven by Research Services (100%).

Most recently: of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities (2026-02-26).

$142M

Market Cap

$7M

Revenue

-$133M

Net Income

Employees181

Fundamentals

How The Business Makes Money

Revenue by Segment

Research Services100%($9M)

Activity

What Changed Recently

Financial Results

Feb 25, 2026

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities

Peer Companies

Company	Price	Change	Market Cap	P/E
ALECAlector, Inc.	$2.40	-5.14%	$265M	-1.5
PRLDPrelude Therapeutics Inco...	$3.51	+1.74%	$196M	-2.0
NKTXNkarta, Inc.	$2.31	+5.71%	$165M	-1.6
ABOSAcumen Pharmaceuticals, I...	$2.70	+5.88%	$164M	-1.2
MOLNMolecular Partners AG	$3.85	-3.87%	$144M	-2.0
CRBPCorbus Pharmaceuticals Ho...	$10.29	+3.11%	$129M	-1.4
VORVor Biopharma Inc.	$18.07	+3.94%	$124M	-0.0
PEPGPepGen Inc.	$1.75	+0.57%	$121M	-2.3

Analyst View

Company Profile

CIK0001434316

ISINUS31189P1021

CUSIP31189P102

Phone858 875 1800

Address12278 Scripps Summit Drive, San Diego, CA, 92131, US

SEC EDGAR